Evidence map›Paper›PMID 41281008›Full record

ArticleCureus2025

The Effect of Cannabis Use Disorder on Mortality and Other Outcomes in Asthma: A Nationwide Analysis (2016-2021).

Samuel Sule-Saa, Pyae Phyo Hein, Jeffrey A Sackey, Daniel Pinkrah, Muhanned Towfig, Anusha Akella, Rebecca Kotei, Richard DiCasoli, Andleeb Sherazi, Kalpana Panigrahi

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Samuel Sule-SaaInternal Medicine, Interfaith Medical Center, Brooklyn, USA.
Pyae Phyo HeinInternal Medicine, Interfaith Medical Center, Brooklyn, USA.
Jeffrey A SackeyInternal Medicine, Interfaith Medical Center, Brooklyn, USA.
Daniel PinkrahMedicine, One Brooklyn Health, Brooklyn, USA.
Muhanned TowfigInternal Medicine, Interfaith Medical Center, Brooklyn, USA.
Anusha AkellaInternal Medicine, Interfaith Medical Center, Brooklyn, USA.
Rebecca KoteiInternal Medicine, Ridge Hospital, Accra, GHA.
Richard DiCasoliInternal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.
Andleeb SheraziCritical Care, One Brooklyn Health, Brooklyn, USA.
Kalpana PanigrahiInternal Medicine, One Brooklyn Health, Brooklyn, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Asthma, a chronic respiratory disease affecting over 300 million individuals globally, significantly impacts the quality of life and healthcare systems. In recent years, cannabis use disorder (CUD) has emerged as a potential complicating factor. Cannabis, though increasingly legalized and perceived as benign, poses risks to respiratory health. This study explores the relationship between CUD and asthma outcomes, focusing on mortality and morbidity trends from 2016 to 2021 in a nationwide context. Objective The objective of this study is to evaluate the impact of CUD on in-hospital mortality, severe asthma exacerbations, and healthcare resource utilization among patients hospitalized for asthma. Methods A retrospective cohort analysis of nationwide asthma admissions between 2016 and 2021 was conducted using the Nationwide Inpatient Sample database. A total of 552,160 cases were stratified into CUD and non-CUD cases. A logistic regression analysis was used to examine the association between CUD and in-hospital mortality as well as the severity of exacerbations among asthmatic patients. We utilized linear regression models to assess the impact of CUD on total charges and length of stay for asthma admissions, adjusting for demographic and hospital-level confounders. Results Of the 552,160 asthma hospitalizations, 4.2% (N = 23,300) of patients had comorbid CUD. CUD patients were younger (a mean age of 35.3 years compared to 51.4 years in non-CUD patients) and predominantly male. Our study showed the odds of in-hospital mortality were significantly greater in patients with CUD (adjusted OR 2.40, 95% CI 1.62-3.55, p < 0.01). CUD was associated with increased odds of severe asthma exacerbations/status asthmaticus (OR 2.39, 95% CI 1.92-2.99, p <.01). However, the adjusted odds ratio (OR) was attenuated (adjusted OR 1.35, 95% CI 1.07-1.71, p = 0.012). Total hospital charges were significantly higher in the CUD group after adjustment (coefficient 2091.31, 95% CI 660.71-3521.9, p = 0.004). There was no significant difference in length of stay between groups (adjusted coefficient -0.06, 95% CI -0.1-0.06, p = 0.7). Conclusion Patients hospitalized for asthma with CUD are associated with higher mortality, increased risk of severe asthma exacerbations, and higher hospital charges. These findings underline the need for targeted interventions in asthmatic patients with CUD to improve clinical outcomes and reduce healthcare burden.

Indexed as

acute asthmacannabis use disorder (cud)mortalitysevere asthma exacerbationstatus asthmaticus

Identifiers

PMID41281008
PMCPMC12631705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.